| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 120 | 2023 | 5171 | 8.270 |
Why?
|
| Lung Neoplasms | 179 | 2023 | 13019 | 7.460 |
Why?
|
| Quinazolines | 45 | 2016 | 1355 | 3.960 |
Why?
|
| Carcinoma, Small Cell | 20 | 2008 | 420 | 3.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 17 | 2023 | 2028 | 2.990 |
Why?
|
| Protein Kinase Inhibitors | 37 | 2023 | 5522 | 2.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 35 | 2023 | 11472 | 1.910 |
Why?
|
| Antineoplastic Agents | 49 | 2020 | 13655 | 1.570 |
Why?
|
| Mutation | 68 | 2023 | 29717 | 1.540 |
Why?
|
| Oximes | 5 | 2021 | 309 | 1.490 |
Why?
|
| Pyrimidinones | 4 | 2021 | 370 | 1.330 |
Why?
|
| Adenocarcinoma | 30 | 2017 | 6347 | 1.270 |
Why?
|
| Tumor Burden | 12 | 2023 | 1905 | 1.230 |
Why?
|
| Imidazoles | 6 | 2021 | 1205 | 1.220 |
Why?
|
| Pyridones | 4 | 2021 | 712 | 1.130 |
Why?
|
| Carcinoma, Large Cell | 4 | 2016 | 113 | 0.980 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 7 | 2012 | 91 | 0.970 |
Why?
|
| Genes, erbB-1 | 7 | 2015 | 161 | 0.860 |
Why?
|
| Receptors, Adrenergic, beta-2 | 3 | 2007 | 202 | 0.800 |
Why?
|
| Neoplasm Staging | 34 | 2020 | 11001 | 0.790 |
Why?
|
| Research Subjects | 1 | 2021 | 238 | 0.700 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2012 | 381 | 0.690 |
Why?
|
| Carcinoid Tumor | 2 | 2014 | 235 | 0.650 |
Why?
|
| Aged | 111 | 2022 | 162944 | 0.640 |
Why?
|
| Middle Aged | 122 | 2022 | 213127 | 0.640 |
Why?
|
| Humans | 242 | 2023 | 742088 | 0.630 |
Why?
|
| Exercise Test | 7 | 2012 | 2075 | 0.610 |
Why?
|
| Clinical Trials as Topic | 12 | 2022 | 7901 | 0.580 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2014 | 4029 | 0.580 |
Why?
|
| Genomics | 15 | 2023 | 5692 | 0.570 |
Why?
|
| Aged, 80 and over | 57 | 2021 | 57683 | 0.570 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2014 | 319 | 0.570 |
Why?
|
| Survival Analysis | 27 | 2021 | 10248 | 0.560 |
Why?
|
| Male | 139 | 2022 | 349538 | 0.540 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 9 | 2022 | 1659 | 0.540 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2020 | 9185 | 0.540 |
Why?
|
| Receptor, erbB-2 | 9 | 2023 | 2410 | 0.530 |
Why?
|
| Female | 145 | 2023 | 379592 | 0.530 |
Why?
|
| Pulmonary Diffusing Capacity | 4 | 2008 | 87 | 0.510 |
Why?
|
| Piperidines | 9 | 2015 | 1602 | 0.510 |
Why?
|
| Prognosis | 34 | 2021 | 29010 | 0.500 |
Why?
|
| Disease-Free Survival | 15 | 2017 | 6891 | 0.500 |
Why?
|
| Adult | 88 | 2021 | 213712 | 0.500 |
Why?
|
| Drug Resistance, Neoplasm | 15 | 2023 | 5163 | 0.500 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 11 | 2023 | 1683 | 0.490 |
Why?
|
| Proto-Oncogene Proteins c-met | 11 | 2019 | 578 | 0.480 |
Why?
|
| Pleural Neoplasms | 6 | 2018 | 607 | 0.480 |
Why?
|
| Neoplasms | 17 | 2022 | 21596 | 0.480 |
Why?
|
| Molecular Targeted Therapy | 12 | 2022 | 2723 | 0.460 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2012 | 895 | 0.460 |
Why?
|
| Mesothelioma | 7 | 2018 | 818 | 0.450 |
Why?
|
| Pneumonectomy | 5 | 2012 | 1093 | 0.440 |
Why?
|
| Biostatistics | 1 | 2014 | 160 | 0.430 |
Why?
|
| Medical Oncology | 3 | 2019 | 2235 | 0.420 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2020 | 448 | 0.420 |
Why?
|
| Survival Rate | 17 | 2021 | 12773 | 0.420 |
Why?
|
| Smoking | 8 | 2021 | 8969 | 0.410 |
Why?
|
| Single-Cell Analysis | 6 | 2021 | 2183 | 0.410 |
Why?
|
| DNA Mutational Analysis | 17 | 2017 | 4187 | 0.400 |
Why?
|
| Proto-Oncogene Proteins | 12 | 2016 | 4553 | 0.400 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 401 | 0.400 |
Why?
|
| Neoplasm Metastasis | 8 | 2020 | 4839 | 0.400 |
Why?
|
| Disease Progression | 21 | 2016 | 13256 | 0.390 |
Why?
|
| Sample Size | 1 | 2014 | 844 | 0.380 |
Why?
|
| ras Proteins | 5 | 2014 | 1060 | 0.370 |
Why?
|
| Paraneoplastic Syndromes | 3 | 2006 | 150 | 0.360 |
Why?
|
| Treatment Outcome | 46 | 2020 | 62966 | 0.360 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2020 | 384 | 0.350 |
Why?
|
| Oncogene Proteins | 2 | 2013 | 749 | 0.350 |
Why?
|
| Melanoma | 3 | 2023 | 5462 | 0.350 |
Why?
|
| Taxoids | 5 | 2013 | 665 | 0.340 |
Why?
|
| Glycine | 3 | 2007 | 671 | 0.330 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2015 | 3502 | 0.320 |
Why?
|
| Heart Failure | 6 | 2010 | 10856 | 0.310 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2014 | 2038 | 0.310 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2022 | 20086 | 0.310 |
Why?
|
| Cohort Studies | 18 | 2022 | 40450 | 0.310 |
Why?
|
| Social Control, Informal | 1 | 2008 | 46 | 0.310 |
Why?
|
| Antibodies, Monoclonal | 9 | 2010 | 9274 | 0.300 |
Why?
|
| Visual Acuity | 1 | 2016 | 2520 | 0.300 |
Why?
|
| Carbon Dioxide | 1 | 2012 | 1141 | 0.300 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2007 | 74 | 0.300 |
Why?
|
| Piperazines | 5 | 2007 | 2488 | 0.300 |
Why?
|
| Pyrimidines | 6 | 2013 | 2933 | 0.290 |
Why?
|
| Maximum Tolerated Dose | 6 | 2017 | 891 | 0.290 |
Why?
|
| Smoking Cessation | 5 | 2012 | 2068 | 0.290 |
Why?
|
| Tumor Escape | 2 | 2021 | 349 | 0.290 |
Why?
|
| Genital Diseases, Female | 1 | 2008 | 197 | 0.290 |
Why?
|
| Law Enforcement | 1 | 2008 | 109 | 0.280 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 1048 | 0.270 |
Why?
|
| Police | 1 | 2008 | 149 | 0.270 |
Why?
|
| In Situ Hybridization, Fluorescence | 7 | 2018 | 2638 | 0.270 |
Why?
|
| Phosphatidylinositol 3-Kinases | 9 | 2023 | 2938 | 0.270 |
Why?
|
| Cardiac Output, Low | 1 | 2006 | 193 | 0.270 |
Why?
|
| Paclitaxel | 8 | 2013 | 1707 | 0.270 |
Why?
|
| Arginine | 2 | 2006 | 944 | 0.270 |
Why?
|
| Medically Underserved Area | 1 | 2008 | 253 | 0.260 |
Why?
|
| Enzyme Inhibitors | 6 | 2012 | 3800 | 0.260 |
Why?
|
| Deoxyribonuclease I | 1 | 2006 | 228 | 0.260 |
Why?
|
| Retinal Artery Occlusion | 1 | 2005 | 74 | 0.250 |
Why?
|
| Sirolimus | 3 | 2012 | 1562 | 0.250 |
Why?
|
| Family Practice | 1 | 2008 | 516 | 0.250 |
Why?
|
| Retrospective Studies | 31 | 2023 | 77098 | 0.250 |
Why?
|
| Cisplatin | 4 | 2018 | 1637 | 0.250 |
Why?
|
| Marijuana Smoking | 1 | 2008 | 252 | 0.240 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 3691 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2021 | 8425 | 0.240 |
Why?
|
| Administration, Oral | 7 | 2017 | 3913 | 0.240 |
Why?
|
| Sunburn | 1 | 2005 | 155 | 0.240 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2004 | 89 | 0.240 |
Why?
|
| Rural Health Services | 1 | 2008 | 379 | 0.240 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 2714 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-kit | 4 | 2005 | 774 | 0.240 |
Why?
|
| Erythema | 1 | 2005 | 254 | 0.230 |
Why?
|
| Sodium Chloride | 1 | 2006 | 625 | 0.230 |
Why?
|
| Tumor Microenvironment | 5 | 2023 | 3564 | 0.230 |
Why?
|
| Hypertension, Pulmonary | 2 | 2012 | 1527 | 0.230 |
Why?
|
| Patient Preference | 1 | 2011 | 886 | 0.230 |
Why?
|
| Lung | 6 | 2020 | 9826 | 0.220 |
Why?
|
| Combined Modality Therapy | 10 | 2018 | 8621 | 0.220 |
Why?
|
| Hyponatremia | 1 | 2006 | 298 | 0.220 |
Why?
|
| Head and Neck Neoplasms | 4 | 2011 | 2712 | 0.220 |
Why?
|
| Sequence Analysis, RNA | 6 | 2021 | 2011 | 0.220 |
Why?
|
| SEER Program | 4 | 2019 | 1507 | 0.220 |
Why?
|
| Gene Rearrangement | 3 | 2016 | 1179 | 0.220 |
Why?
|
| Meningeal Neoplasms | 2 | 2015 | 1241 | 0.210 |
Why?
|
| Leptin | 2 | 2008 | 1593 | 0.210 |
Why?
|
| Mutagenesis, Insertional | 2 | 2017 | 655 | 0.210 |
Why?
|
| Guidelines as Topic | 2 | 2009 | 1402 | 0.210 |
Why?
|
| Genome, Human | 3 | 2012 | 4420 | 0.210 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2019 | 3585 | 0.210 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2003 | 839 | 0.200 |
Why?
|
| Genotype | 9 | 2015 | 12946 | 0.200 |
Why?
|
| Immunohistochemistry | 10 | 2019 | 11363 | 0.200 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 9410 | 0.200 |
Why?
|
| Cell Line, Tumor | 22 | 2021 | 16665 | 0.200 |
Why?
|
| Heart Rate | 3 | 2009 | 4091 | 0.190 |
Why?
|
| Genes, erbB-2 | 3 | 2017 | 162 | 0.190 |
Why?
|
| Apolipoproteins E | 1 | 2007 | 1438 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2015 | 544 | 0.190 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 4 | 2018 | 890 | 0.190 |
Why?
|
| Edema | 1 | 2005 | 790 | 0.190 |
Why?
|
| Exons | 6 | 2019 | 2431 | 0.190 |
Why?
|
| Quinolones | 1 | 2004 | 366 | 0.190 |
Why?
|
| Cell Proliferation | 7 | 2015 | 10472 | 0.190 |
Why?
|
| Sodium | 1 | 2006 | 1627 | 0.190 |
Why?
|
| Drug Therapy, Combination | 3 | 2018 | 6483 | 0.190 |
Why?
|
| Brain Neoplasms | 7 | 2022 | 8829 | 0.190 |
Why?
|
| Patient Selection | 3 | 2012 | 4214 | 0.180 |
Why?
|
| Respiratory Mucosa | 1 | 2003 | 427 | 0.180 |
Why?
|
| Carbamates | 1 | 2021 | 195 | 0.180 |
Why?
|
| Off-Label Use | 1 | 2022 | 169 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2012 | 3471 | 0.180 |
Why?
|
| Thoracic Neoplasms | 1 | 2022 | 268 | 0.180 |
Why?
|
| Oxygen | 1 | 2012 | 4169 | 0.180 |
Why?
|
| Gene Amplification | 6 | 2014 | 1062 | 0.180 |
Why?
|
| Genes, ras | 6 | 2015 | 691 | 0.180 |
Why?
|
| Cystadenoma, Serous | 1 | 2020 | 102 | 0.180 |
Why?
|
| Follow-Up Studies | 16 | 2019 | 39004 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2017 | 10943 | 0.170 |
Why?
|
| Molecular Imaging | 2 | 2021 | 831 | 0.170 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2021 | 1631 | 0.170 |
Why?
|
| Preoperative Care | 1 | 2008 | 2245 | 0.170 |
Why?
|
| Pneumothorax | 1 | 2022 | 379 | 0.170 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 210 | 0.170 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2003 | 623 | 0.160 |
Why?
|
| Life Expectancy | 1 | 2005 | 1183 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 4 | 2022 | 2721 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2020 | 6534 | 0.160 |
Why?
|
| Health Services | 1 | 2004 | 758 | 0.160 |
Why?
|
| Receptor, erbB-3 | 4 | 2007 | 142 | 0.160 |
Why?
|
| Genes, p53 | 3 | 2012 | 755 | 0.160 |
Why?
|
| Ascites | 1 | 2020 | 344 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2009 | 1769 | 0.160 |
Why?
|
| Carboplatin | 7 | 2013 | 799 | 0.160 |
Why?
|
| MAP Kinase Kinase 1 | 4 | 2015 | 337 | 0.150 |
Why?
|
| BRCA2 Protein | 1 | 2022 | 790 | 0.150 |
Why?
|
| Genetic Testing | 3 | 2022 | 3439 | 0.150 |
Why?
|
| Pteridines | 1 | 2016 | 45 | 0.140 |
Why?
|
| Amino Acid Substitution | 3 | 2018 | 1792 | 0.140 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 971 | 0.140 |
Why?
|
| DNA, Neoplasm | 5 | 2016 | 1758 | 0.140 |
Why?
|
| Hyperthermia, Induced | 2 | 2018 | 401 | 0.140 |
Why?
|
| Benzimidazoles | 1 | 2021 | 848 | 0.140 |
Why?
|
| Deoxycytidine | 2 | 2018 | 824 | 0.140 |
Why?
|
| Protein-Tyrosine Kinases | 5 | 2016 | 2455 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2018 | 322 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2007 | 2059 | 0.140 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 351 | 0.130 |
Why?
|
| Positron-Emission Tomography | 4 | 2022 | 6259 | 0.130 |
Why?
|
| Respiratory Function Tests | 4 | 2009 | 1613 | 0.130 |
Why?
|
| Sulfones | 3 | 2007 | 437 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2003 | 1052 | 0.130 |
Why?
|
| Mutation, Missense | 4 | 2013 | 2556 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2022 | 1145 | 0.130 |
Why?
|
| Receptor, trkA | 1 | 2016 | 164 | 0.130 |
Why?
|
| Prospective Studies | 14 | 2021 | 53187 | 0.130 |
Why?
|
| Dimerization | 2 | 2007 | 893 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2018 | 535 | 0.130 |
Why?
|
| Ovarian Neoplasms | 2 | 2023 | 4823 | 0.130 |
Why?
|
| Protein Structure, Tertiary | 6 | 2008 | 3847 | 0.130 |
Why?
|
| Proportional Hazards Models | 6 | 2013 | 12344 | 0.130 |
Why?
|
| Confidence Intervals | 2 | 2017 | 2970 | 0.120 |
Why?
|
| Minnesota | 4 | 2009 | 343 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2015 | 9941 | 0.120 |
Why?
|
| Social Class | 1 | 2004 | 1995 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2017 | 4929 | 0.120 |
Why?
|
| Young Adult | 11 | 2020 | 56350 | 0.120 |
Why?
|
| Genes, p16 | 2 | 2012 | 157 | 0.120 |
Why?
|
| Phosphorylation | 13 | 2016 | 8436 | 0.120 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2009 | 627 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 6171 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2010 | 15494 | 0.120 |
Why?
|
| Social Support | 1 | 2004 | 2117 | 0.120 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 725 | 0.120 |
Why?
|
| New York City | 2 | 2008 | 706 | 0.120 |
Why?
|
| Registries | 1 | 2009 | 8077 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2020 | 2940 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 731 | 0.110 |
Why?
|
| Biopsy | 4 | 2016 | 6756 | 0.110 |
Why?
|
| Recovery of Function | 3 | 2009 | 2924 | 0.110 |
Why?
|
| Feasibility Studies | 5 | 2019 | 5062 | 0.110 |
Why?
|
| Apoptosis | 5 | 2006 | 9715 | 0.110 |
Why?
|
| Signal Transduction | 13 | 2020 | 23387 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 6 | 2020 | 6313 | 0.110 |
Why?
|
| Benzamides | 5 | 2007 | 1378 | 0.110 |
Why?
|
| Genes, Neoplasm | 2 | 2012 | 376 | 0.110 |
Why?
|
| Mass Screening | 4 | 2011 | 5238 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2015 | 2107 | 0.110 |
Why?
|
| Exercise Tolerance | 3 | 2008 | 770 | 0.110 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2015 | 740 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2016 | 933 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 2 | 2021 | 5249 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 9 | 2015 | 2502 | 0.100 |
Why?
|
| Case-Control Studies | 7 | 2020 | 21719 | 0.100 |
Why?
|
| Oxygen Consumption | 2 | 2009 | 1869 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2021 | 1932 | 0.100 |
Why?
|
| Carcinoma | 1 | 2023 | 2374 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2013 | 220 | 0.100 |
Why?
|
| Receptors, Mitogen | 1 | 2011 | 62 | 0.100 |
Why?
|
| Pneumonia | 1 | 2023 | 2117 | 0.100 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2020 | 1622 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 2020 | 2968 | 0.100 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2012 | 101 | 0.100 |
Why?
|
| Epoprostenol | 1 | 2012 | 254 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2022 | 17400 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2008 | 1239 | 0.100 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 712 | 0.100 |
Why?
|
| Insurance Coverage | 1 | 2022 | 1895 | 0.090 |
Why?
|
| United States | 11 | 2022 | 69693 | 0.090 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 2885 | 0.090 |
Why?
|
| Epidermal Growth Factor | 2 | 2004 | 709 | 0.090 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 2906 | 0.090 |
Why?
|
| Lung Transplantation | 3 | 2009 | 1155 | 0.090 |
Why?
|
| Double-Blind Method | 4 | 2013 | 12017 | 0.090 |
Why?
|
| Genetic Variation | 3 | 2018 | 6540 | 0.090 |
Why?
|
| Aneuploidy | 2 | 2023 | 530 | 0.090 |
Why?
|
| Iohexol | 1 | 2010 | 196 | 0.090 |
Why?
|
| Risk Assessment | 6 | 2012 | 23320 | 0.090 |
Why?
|
| Thionucleotides | 1 | 2009 | 107 | 0.090 |
Why?
|
| Forecasting | 1 | 2019 | 2948 | 0.090 |
Why?
|
| Liver Neoplasms | 2 | 2015 | 4249 | 0.090 |
Why?
|
| Sensitivity and Specificity | 8 | 2010 | 14720 | 0.090 |
Why?
|
| Adolescent | 10 | 2022 | 85649 | 0.090 |
Why?
|
| Cytoskeleton | 3 | 2003 | 1185 | 0.090 |
Why?
|
| Estrogen Receptor beta | 1 | 2010 | 175 | 0.090 |
Why?
|
| Amifostine | 1 | 2009 | 41 | 0.090 |
Why?
|
| Health Expenditures | 1 | 2022 | 2346 | 0.090 |
Why?
|
| Massachusetts | 3 | 2021 | 8662 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3612 | 0.090 |
Why?
|
| Mice, Nude | 4 | 2020 | 3689 | 0.090 |
Why?
|
| Severity of Illness Index | 5 | 2014 | 15530 | 0.080 |
Why?
|
| Thiazoles | 2 | 2013 | 1484 | 0.080 |
Why?
|
| Withholding Treatment | 1 | 2013 | 598 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2009 | 203 | 0.080 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2009 | 664 | 0.080 |
Why?
|
| Metabolic Clearance Rate | 2 | 2006 | 379 | 0.080 |
Why?
|
| Radiation-Protective Agents | 1 | 2009 | 89 | 0.080 |
Why?
|
| Vital Capacity | 2 | 2009 | 922 | 0.080 |
Why?
|
| Academic Medical Centers | 2 | 2022 | 2749 | 0.080 |
Why?
|
| Phenylethanolamine N-Methyltransferase | 1 | 2008 | 18 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2017 | 2948 | 0.080 |
Why?
|
| Animals | 23 | 2021 | 168561 | 0.080 |
Why?
|
| Online Systems | 1 | 2009 | 184 | 0.080 |
Why?
|
| Tobacco Use Disorder | 2 | 2011 | 685 | 0.080 |
Why?
|
| Heart-Lung Transplantation | 1 | 2008 | 71 | 0.080 |
Why?
|
| Protein Multimerization | 1 | 2013 | 971 | 0.080 |
Why?
|
| Algorithms | 3 | 2021 | 13853 | 0.080 |
Why?
|
| Cytoprotection | 1 | 2009 | 210 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2012 | 2335 | 0.080 |
Why?
|
| Electrocardiography | 4 | 2009 | 6440 | 0.080 |
Why?
|
| Drug Industry | 1 | 2014 | 744 | 0.080 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 1183 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2014 | 6365 | 0.080 |
Why?
|
| Disease Management | 1 | 2018 | 2450 | 0.080 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2009 | 282 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2007 | 2013 | 0.080 |
Why?
|
| Glioma | 1 | 2022 | 3388 | 0.080 |
Why?
|
| Anthropology, Cultural | 1 | 2008 | 99 | 0.080 |
Why?
|
| Observer Variation | 2 | 2010 | 2593 | 0.080 |
Why?
|
| Local Government | 1 | 2008 | 79 | 0.080 |
Why?
|
| Lung Diseases | 2 | 2009 | 1884 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 2004 | 4250 | 0.070 |
Why?
|
| Risk Factors | 8 | 2013 | 72145 | 0.070 |
Why?
|
| Poverty | 1 | 2019 | 2646 | 0.070 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2007 | 96 | 0.070 |
Why?
|
| Tomography, Spiral Computed | 1 | 2008 | 279 | 0.070 |
Why?
|
| Recurrence | 3 | 2016 | 8333 | 0.070 |
Why?
|
| Predictive Value of Tests | 6 | 2009 | 15056 | 0.070 |
Why?
|
| Remission Induction | 3 | 2016 | 2384 | 0.070 |
Why?
|
| Breast Neoplasms | 4 | 2023 | 20774 | 0.070 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2006 | 141 | 0.070 |
Why?
|
| Friends | 1 | 2008 | 153 | 0.070 |
Why?
|
| Insulin Infusion Systems | 1 | 2008 | 212 | 0.070 |
Why?
|
| Pyridines | 2 | 2016 | 2818 | 0.070 |
Why?
|
| Parity | 1 | 2010 | 929 | 0.070 |
Why?
|
| Haplotypes | 2 | 2010 | 2781 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 3915 | 0.070 |
Why?
|
| Mice | 16 | 2021 | 81045 | 0.070 |
Why?
|
| Forced Expiratory Volume | 2 | 2009 | 1741 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2016 | 1970 | 0.070 |
Why?
|
| Drug Design | 1 | 2012 | 1078 | 0.070 |
Why?
|
| Polymorphism, Genetic | 2 | 2008 | 4328 | 0.070 |
Why?
|
| Models, Molecular | 4 | 2016 | 5454 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2021 | 12695 | 0.070 |
Why?
|
| Boston | 2 | 2021 | 9305 | 0.070 |
Why?
|
| Receptors, Growth Factor | 1 | 2007 | 334 | 0.070 |
Why?
|
| Arginine Vasopressin | 1 | 2006 | 130 | 0.070 |
Why?
|
| Oncogenes | 2 | 2022 | 1263 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2005 | 459 | 0.070 |
Why?
|
| Stereotyping | 1 | 2008 | 241 | 0.070 |
Why?
|
| Bone Neoplasms | 2 | 2015 | 2522 | 0.070 |
Why?
|
| Sex Factors | 4 | 2015 | 10392 | 0.070 |
Why?
|
| Loss of Heterozygosity | 2 | 2007 | 678 | 0.070 |
Why?
|
| Leg Dermatoses | 1 | 2005 | 20 | 0.070 |
Why?
|
| Lung Volume Measurements | 1 | 2006 | 377 | 0.070 |
Why?
|
| Radiographic Image Enhancement | 1 | 2010 | 885 | 0.070 |
Why?
|
| Government Programs | 1 | 2008 | 275 | 0.070 |
Why?
|
| NIH 3T3 Cells | 3 | 2013 | 677 | 0.070 |
Why?
|
| Family Relations | 1 | 2008 | 321 | 0.070 |
Why?
|
| Intraoperative Care | 1 | 2009 | 766 | 0.070 |
Why?
|
| Germ-Line Mutation | 3 | 2022 | 1786 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 3444 | 0.060 |
Why?
|
| Time Factors | 8 | 2012 | 40054 | 0.060 |
Why?
|
| Paraffin Embedding | 1 | 2006 | 299 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 10163 | 0.060 |
Why?
|
| Cyclic GMP | 1 | 2006 | 408 | 0.060 |
Why?
|
| Physical Exertion | 1 | 2007 | 695 | 0.060 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2006 | 393 | 0.060 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2005 | 270 | 0.060 |
Why?
|
| Blood Gas Analysis | 1 | 2005 | 381 | 0.060 |
Why?
|
| Epinephrine | 1 | 2008 | 793 | 0.060 |
Why?
|
| Farnesyltranstransferase | 1 | 2004 | 76 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2012 | 2751 | 0.060 |
Why?
|
| Biopsy, Needle | 2 | 2006 | 1640 | 0.060 |
Why?
|
| Walking | 1 | 2012 | 1177 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 19862 | 0.060 |
Why?
|
| Formaldehyde | 1 | 2006 | 353 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2008 | 783 | 0.060 |
Why?
|
| Infusions, Intravenous | 2 | 2006 | 2271 | 0.060 |
Why?
|
| Antibodies, Neoplasm | 1 | 2005 | 286 | 0.060 |
Why?
|
| Schools, Medical | 1 | 2010 | 878 | 0.060 |
Why?
|
| Antilymphocyte Serum | 1 | 2005 | 491 | 0.060 |
Why?
|
| Ventricular Function, Right | 1 | 2007 | 592 | 0.060 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 1573 | 0.060 |
Why?
|
| Nuclear Proteins | 3 | 2023 | 5851 | 0.060 |
Why?
|
| Blood Pressure | 3 | 2009 | 8541 | 0.060 |
Why?
|
| Genes, MDR | 1 | 2003 | 37 | 0.060 |
Why?
|
| Public Policy | 1 | 2008 | 572 | 0.060 |
Why?
|
| Denmark | 1 | 2005 | 736 | 0.060 |
Why?
|
| Pulmonary Ventilation | 1 | 2005 | 372 | 0.060 |
Why?
|
| Echocardiography, Doppler | 1 | 2007 | 934 | 0.050 |
Why?
|
| Peer Group | 1 | 2008 | 635 | 0.050 |
Why?
|
| Counseling | 1 | 2011 | 1521 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2006 | 595 | 0.050 |
Why?
|
| Spirometry | 1 | 2005 | 862 | 0.050 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2003 | 106 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 3 | 2010 | 7276 | 0.050 |
Why?
|
| Louisiana | 1 | 2022 | 109 | 0.050 |
Why?
|
| Illinois | 1 | 2022 | 119 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2008 | 783 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 2043 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2007 | 1284 | 0.050 |
Why?
|
| Transcription Factors | 4 | 2023 | 12164 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 1574 | 0.050 |
Why?
|
| Myocardial Contraction | 1 | 2007 | 1585 | 0.050 |
Why?
|
| Homozygote | 1 | 2006 | 1777 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2010 | 1581 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2006 | 1470 | 0.050 |
Why?
|
| Research | 3 | 2010 | 1999 | 0.050 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2002 | 228 | 0.050 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2023 | 338 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2005 | 741 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 6754 | 0.050 |
Why?
|
| DNA Copy Number Variations | 2 | 2020 | 1940 | 0.050 |
Why?
|
| Italy | 1 | 2003 | 828 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 24913 | 0.050 |
Why?
|
| Contrast Media | 2 | 2014 | 5295 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 1675 | 0.050 |
Why?
|
| Proto-Oncogenes | 2 | 2014 | 321 | 0.050 |
Why?
|
| Aldosterone | 1 | 2006 | 876 | 0.050 |
Why?
|
| Cell Division | 3 | 2003 | 4564 | 0.050 |
Why?
|
| Indoles | 2 | 2007 | 1834 | 0.050 |
Why?
|
| Cell Compartmentation | 1 | 2021 | 402 | 0.050 |
Why?
|
| Endothelial Cells | 2 | 2021 | 3455 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 2275 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2008 | 2260 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 1799 | 0.050 |
Why?
|
| Radiography, Thoracic | 1 | 2007 | 1265 | 0.050 |
Why?
|
| Cell Cycle | 3 | 2005 | 2964 | 0.050 |
Why?
|
| Janus Kinase 1 | 1 | 2020 | 104 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 3862 | 0.050 |
Why?
|
| Heterozygote | 1 | 2007 | 2790 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2007 | 1638 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 364 | 0.050 |
Why?
|
| Prevalence | 2 | 2015 | 15194 | 0.040 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2020 | 103 | 0.040 |
Why?
|
| Chromosomes | 1 | 2023 | 595 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 3611 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2016 | 2615 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2011 | 2921 | 0.040 |
Why?
|
| STAT Transcription Factors | 1 | 2020 | 182 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 2012 | 2370 | 0.040 |
Why?
|
| Freezing | 1 | 2020 | 303 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 3507 | 0.040 |
Why?
|
| Heart Atria | 1 | 2005 | 1348 | 0.040 |
Why?
|
| Postoperative Complications | 4 | 2009 | 15244 | 0.040 |
Why?
|
| Dendritic Spines | 1 | 2021 | 233 | 0.040 |
Why?
|
| Atlases as Topic | 1 | 2020 | 237 | 0.040 |
Why?
|
| Genes, myc | 1 | 2020 | 399 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2008 | 1237 | 0.040 |
Why?
|
| Health Promotion | 1 | 2011 | 2194 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2003 | 1661 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2014 | 7716 | 0.040 |
Why?
|
| Education, Medical | 1 | 2010 | 1717 | 0.040 |
Why?
|
| Random Allocation | 1 | 2003 | 2425 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 3 | 2019 | 4801 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2021 | 424 | 0.040 |
Why?
|
| Computational Biology | 2 | 2021 | 3518 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2005 | 1820 | 0.040 |
Why?
|
| Blotting, Western | 4 | 2009 | 5180 | 0.040 |
Why?
|
| Risk | 1 | 2010 | 9679 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2021 | 808 | 0.040 |
Why?
|
| Cell Movement | 5 | 2015 | 5212 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 1021 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2002 | 726 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 628 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2023 | 861 | 0.040 |
Why?
|
| Placebos | 3 | 2007 | 1677 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2022 | 1086 | 0.040 |
Why?
|
| Curriculum | 1 | 2010 | 3589 | 0.040 |
Why?
|
| Cytokines | 2 | 2009 | 7317 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2010 | 4029 | 0.040 |
Why?
|
| Chemokines | 1 | 2021 | 954 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2021 | 1341 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 1653 | 0.040 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2005 | 1263 | 0.040 |
Why?
|
| Coronary Artery Disease | 2 | 2008 | 6454 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2021 | 804 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 2021 | 3199 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2023 | 1811 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 2 | 2018 | 1525 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 1434 | 0.030 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2021 | 838 | 0.030 |
Why?
|
| Graft Rejection | 2 | 2008 | 4393 | 0.030 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2021 | 963 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2021 | 1353 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 2866 | 0.030 |
Why?
|
| Immunity | 1 | 2021 | 1011 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3920 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1038 | 0.030 |
Why?
|
| Base Sequence | 2 | 2022 | 12797 | 0.030 |
Why?
|
| Heart Ventricles | 1 | 2007 | 3801 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2008 | 6191 | 0.030 |
Why?
|
| Alleles | 1 | 2006 | 6931 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2016 | 563 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2002 | 1525 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 2211 | 0.030 |
Why?
|
| Data Collection | 1 | 2004 | 3339 | 0.030 |
Why?
|
| Epitopes | 1 | 2021 | 2569 | 0.030 |
Why?
|
| Transfection | 3 | 2009 | 5892 | 0.030 |
Why?
|
| Chromones | 2 | 2005 | 154 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2009 | 6078 | 0.030 |
Why?
|
| Electronic Health Records | 2 | 2021 | 4440 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2007 | 4983 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2015 | 2713 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2007 | 5978 | 0.030 |
Why?
|
| Comorbidity | 1 | 2008 | 10372 | 0.030 |
Why?
|
| RNA Interference | 3 | 2007 | 2890 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2005 | 480 | 0.030 |
Why?
|
| ROC Curve | 1 | 2021 | 3528 | 0.030 |
Why?
|
| Proteomics | 1 | 2006 | 3618 | 0.030 |
Why?
|
| Insulin | 1 | 2008 | 6575 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2008 | 1097 | 0.030 |
Why?
|
| CHO Cells | 2 | 2007 | 1407 | 0.030 |
Why?
|
| Immunotherapy | 2 | 2019 | 4414 | 0.030 |
Why?
|
| Echocardiography | 1 | 2005 | 5097 | 0.030 |
Why?
|
| Visual Cortex | 1 | 2021 | 1149 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 697 | 0.030 |
Why?
|
| DNA | 1 | 2006 | 7289 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2015 | 508 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 713 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2016 | 648 | 0.030 |
Why?
|
| Natural Language Processing | 1 | 2020 | 1035 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 4147 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 503 | 0.030 |
Why?
|
| Cricetinae | 2 | 2007 | 2471 | 0.030 |
Why?
|
| Research Design | 2 | 2005 | 5979 | 0.030 |
Why?
|
| Early Detection of Cancer | 2 | 2019 | 3070 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 4751 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 732 | 0.030 |
Why?
|
| Stem Cells | 1 | 2005 | 3563 | 0.030 |
Why?
|
| Monocytes | 1 | 2021 | 2593 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 627 | 0.030 |
Why?
|
| Exercise | 1 | 2008 | 5611 | 0.020 |
Why?
|
| Protein Conformation | 2 | 2013 | 4013 | 0.020 |
Why?
|
| Codon | 1 | 2013 | 611 | 0.020 |
Why?
|
| Cotinine | 1 | 2011 | 206 | 0.020 |
Why?
|
| Morpholines | 2 | 2005 | 561 | 0.020 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 12242 | 0.020 |
Why?
|
| Survivors | 1 | 2021 | 2286 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 3164 | 0.020 |
Why?
|
| Health Status | 1 | 2004 | 4030 | 0.020 |
Why?
|
| Virginia | 1 | 2010 | 121 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2020 | 4200 | 0.020 |
Why?
|
| Sequence Deletion | 2 | 2006 | 1526 | 0.020 |
Why?
|
| Small Molecule Libraries | 1 | 2016 | 721 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 3133 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2017 | 1780 | 0.020 |
Why?
|
| Point Mutation | 2 | 2006 | 1624 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 4554 | 0.020 |
Why?
|
| Western World | 1 | 2009 | 27 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2007 | 11470 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2009 | 3557 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2005 | 692 | 0.020 |
Why?
|
| Calibration | 1 | 2012 | 815 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2020 | 4143 | 0.020 |
Why?
|
| Phenotype | 2 | 2008 | 16331 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 1707 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2008 | 5724 | 0.020 |
Why?
|
| Child | 3 | 2022 | 77478 | 0.020 |
Why?
|
| Neutrophils | 1 | 2021 | 3711 | 0.020 |
Why?
|
| DNA Repair | 1 | 2018 | 2042 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2009 | 295 | 0.020 |
Why?
|
| Incidence | 1 | 2007 | 20928 | 0.020 |
Why?
|
| Carbon Monoxide | 1 | 2011 | 531 | 0.020 |
Why?
|
| Proteins | 1 | 2023 | 6096 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2011 | 551 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2013 | 2837 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2006 | 3701 | 0.020 |
Why?
|
| Therapeutic Irrigation | 1 | 2009 | 300 | 0.020 |
Why?
|
| Disease Models, Animal | 3 | 2016 | 18006 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2003 | 5100 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2009 | 520 | 0.020 |
Why?
|
| PC12 Cells | 1 | 2008 | 330 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1503 | 0.020 |
Why?
|
| Propensity Score | 1 | 2014 | 1771 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 7721 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2013 | 13814 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2007 | 300 | 0.020 |
Why?
|
| Graft Survival | 2 | 2008 | 3733 | 0.020 |
Why?
|
| Cell Adhesion | 2 | 2003 | 3139 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 252 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 18112 | 0.020 |
Why?
|
| COS Cells | 1 | 2008 | 1160 | 0.020 |
Why?
|
| Doxycycline | 1 | 2007 | 326 | 0.020 |
Why?
|
| Butadienes | 1 | 2005 | 110 | 0.020 |
Why?
|
| Cell Line | 1 | 2020 | 15994 | 0.020 |
Why?
|
| Norepinephrine | 1 | 2008 | 909 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2005 | 135 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 21821 | 0.020 |
Why?
|
| Cricetulus | 1 | 2007 | 817 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2011 | 1679 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 7770 | 0.020 |
Why?
|
| Genome-Wide Association Study | 2 | 2015 | 12220 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2020 | 14554 | 0.020 |
Why?
|
| Metoprolol | 1 | 2005 | 93 | 0.020 |
Why?
|
| Models, Structural | 1 | 2005 | 361 | 0.020 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2005 | 114 | 0.020 |
Why?
|
| Vincristine | 1 | 2007 | 1036 | 0.020 |
Why?
|
| Propanolamines | 1 | 2005 | 167 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2008 | 1723 | 0.020 |
Why?
|
| Cell Shape | 1 | 2005 | 375 | 0.020 |
Why?
|
| Urogenital Neoplasms | 1 | 2005 | 135 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2009 | 933 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 1342 | 0.010 |
Why?
|
| Purines | 1 | 2007 | 593 | 0.010 |
Why?
|
| Mice, Transgenic | 2 | 2007 | 9735 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 2658 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3465 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2008 | 1251 | 0.010 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2007 | 608 | 0.010 |
Why?
|
| Paxillin | 1 | 2003 | 86 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2008 | 1547 | 0.010 |
Why?
|
| Organ Size | 1 | 2009 | 2253 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 625 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 3151 | 0.010 |
Why?
|
| Carbazoles | 1 | 2005 | 226 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 2005 | 396 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2009 | 1355 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 187 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 2007 | 976 | 0.010 |
Why?
|
| Radiography | 1 | 2014 | 7010 | 0.010 |
Why?
|
| Probability | 1 | 2008 | 2502 | 0.010 |
Why?
|
| Flow Cytometry | 2 | 2005 | 5975 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 2007 | 1400 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 1780 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 2006 | 435 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2002 | 104 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 15108 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 1374 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 1827 | 0.010 |
Why?
|
| Body Height | 1 | 2009 | 1574 | 0.010 |
Why?
|
| Quinones | 1 | 2002 | 76 | 0.010 |
Why?
|
| Nausea | 1 | 2005 | 665 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 495 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2005 | 768 | 0.010 |
Why?
|
| Pandemics | 1 | 2022 | 8328 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2004 | 800 | 0.010 |
Why?
|
| Inflammation | 1 | 2021 | 10578 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2004 | 936 | 0.010 |
Why?
|
| Benzoquinones | 1 | 2002 | 201 | 0.010 |
Why?
|
| Quinolines | 1 | 2006 | 719 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2004 | 894 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2005 | 498 | 0.010 |
Why?
|
| Medicare | 1 | 2019 | 6532 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2008 | 3587 | 0.010 |
Why?
|
| Chemokines, CXC | 1 | 2002 | 422 | 0.010 |
Why?
|
| World Health Organization | 1 | 2006 | 1317 | 0.010 |
Why?
|
| Age Factors | 2 | 2008 | 18355 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 12958 | 0.010 |
Why?
|
| Prednisone | 1 | 2005 | 1567 | 0.010 |
Why?
|
| Cell Size | 1 | 2002 | 643 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2002 | 462 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2005 | 1907 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2007 | 2215 | 0.010 |
Why?
|
| Genital Neoplasms, Female | 1 | 2005 | 516 | 0.010 |
Why?
|
| Nitriles | 1 | 2005 | 952 | 0.010 |
Why?
|
| Lactams, Macrocyclic | 1 | 2002 | 319 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2012 | 3584 | 0.010 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 1668 | 0.010 |
Why?
|
| Japan | 1 | 2004 | 1360 | 0.010 |
Why?
|
| Health Policy | 1 | 2012 | 2657 | 0.010 |
Why?
|
| Infant | 1 | 2021 | 35070 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2009 | 2205 | 0.010 |
Why?
|
| Rats | 2 | 2008 | 24265 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2021 | 40955 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 5385 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2011 | 3740 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2015 | 7873 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 1727 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2002 | 1683 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2009 | 2585 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2003 | 1118 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 2372 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 1363 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2005 | 987 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2013 | 19223 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2004 | 2633 | 0.010 |
Why?
|
| Tyrosine | 1 | 2002 | 1460 | 0.010 |
Why?
|
| Antibodies | 1 | 2005 | 2459 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 2906 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2012 | 4595 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 3328 | 0.010 |
Why?
|
| Genome | 1 | 2004 | 1803 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 4742 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 2633 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2003 | 2440 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2002 | 2077 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2005 | 1820 | 0.010 |
Why?
|
| Kidney | 1 | 2009 | 7167 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 13403 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 3766 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 2005 | 3656 | 0.010 |
Why?
|
| Software | 1 | 2004 | 4434 | 0.010 |
Why?
|
| Palliative Care | 1 | 2004 | 3478 | 0.010 |
Why?
|
| Pregnancy | 1 | 2010 | 29087 | 0.000 |
Why?
|
| Skin Neoplasms | 1 | 2005 | 5662 | 0.000 |
Why?
|
| Quality of Life | 1 | 2005 | 12730 | 0.000 |
Why?
|